Gastric Acid/secretion; Gastroesophageal Reflux/drug therapy/metabolism; Humans; Peptic Ulcer/drug therapy/metabolism; Primary Health Care/methods; Proton Pump Inhibitors/therapeutic use
Abstract :
[en] Heartburn, reflux and epigastric pain are frequently encountered symptoms in primary care medicine. Acid peptic diseases such as peptic ulcer and gastrointestinal reflux disease have a high prevalence, can have important impact on patient quality of life and represent a considerable health care cost. Proton pump inhibitors (PPIs) are the most potent pharmacological inhibitors of gastric acid secretion currently available and are the mainstay medical therapy for acid peptic diseases. This review summarizes current evidence on treatment of acid-peptic diseases with proton pump inhibitors and provides primary care clinicians with best practice guidelines for optimal use of these drugs.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Tack, Jacques ; Université de Liège - ULiège > Département ArGEnCo > Département ArGEnCo
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Persy, V.
Urbain, D.
Language :
English
Title :
Optimal use of proton pump inhibitors for treating acid peptic diseases in primary care.
Federale Overheidsdienst Sociale Zekerheid: Aanbevelingen over het gebruik van protonpompinhibitoren [Internet]. RIZIV, 2010 [cited 2012 May 5], 180. Available from: http://www.riziv.fgov.be/drug/nl/drugs/recommendation/ pdf/recommandations_PPI_IPP.pdf
BOPARAI V., RAJAGOPALAN J., TRIADAFILOPOULOS G. Guide to the use of proton pump inhibitors in adult patients. [Internet]. Drugs, 2008 [cited 2012 May 21], 68: 925-47.
GRAHAM D.Y., AGRAWAL N.M., CAMPBELL D.R., HABER M.M., COLLIS C., LUKASIK N.L. et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole. [Internet]. Arch. Intern. Med., 2002 [cited 2012 Jul 27], 162: 169-75.
GISBERT J.P., CALVET X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment. Pharmacol. Ther., 2011, 34: 1255-68.
GISBERT J.P., KHORRAMI S., CALVET X., GABRIEL R., CARBALLO F., PAJARES J.M. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists-their efficacy with antibiotics in Helicobacter pylori eradication. Aliment. Pharmacol. Ther., 2003, 18: 757-766.
TOMITA T., FUKUDA Y., TAMURA K., TANAKA J., HIDA N., KOSAKA T. et al. Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. [Internet]. Aliment. Pharmacol. Ther., 2002 [cited 2012 Jul 27], 16 Suppl 2: 204-9.
OHARA T., MORISHITA T., SUZUKI H., MASAOKA T., ISHII H. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond ac [Internet]. Hepatogastroenterology [cited 2012 Jul 27], 51: 338-42.
MOAYYEDI P., SANTANA J., KHAN M., PRESTON C., DONNELLAN C. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst. Rev., 2011: CD003244.
TACK J., FASS R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? [Internet]. Aliment. Pharmacol. Ther., 2004 [cited 2012 Aug 10], 19 Suppl 1: 28-34.
RIBOLSI M., EMERENZIANI S., PETITTI T., ADDARII M.C., BALESTRIERI P., CICALA M. Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responders to proton pump inhibitors. Dig. Liver Dis., 2012, 44: 549-54.
SCARPIGNATO C. Poor effectiveness of proton pump inhibitors in nonerosive reflux disease: the truth in the end! Neurogastroenterol. Motil., 2012, 24: 697-704.
WEIJENBORG P.W., CREMONINI F., SMOUT A.J.P.M., BREDENOORD A.J. PPI therapy is equally effective in well-defined nonerosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol. Motil., 2012, 24: 747-e350.
DICKMAN R., BOAZ M., AIZIC S., BENIASHVILI Z., FASS R., NIV Y. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J. Neurogastroenterol. Motil., 2011, 17: 387-94.
RUIGÓMEZ A., JOHANSSON S., WERNERSSON B., FERNÁNDEZ CANTERO O., GARCÍA RODRÍGUEZ L.A. Gastroesophageal reflux disease in primary care: Using changes in proton pump inhibitor therapy as an indicator of partial response. Scand. J. Gastroenterol., 2012 DOI: 10.3109/00365521.2012.679682
TACK J., TALLEY N.J., CAMILLERI M., HOLTMANN G., HU P., MALAGELADA J.-R. et al. Functional gastroduodenal disorders. Gastroenterology, 2006, 130: 1466-79.
CHOUNG R.S., LOCKE G.R., SCHLECK C.D., ZINSMEISTER A.R., TALLEY N.J. Overlap of dyspepsia and gastroesophageal reflux in the general population: one disease or distinct entities? Neurogastroenterology & Motility, 2012, 24: 229-e106.
PIESSEVAUX H., DE WINTER B., LOUIS E., MULS V., DE LOOZE D., PELCKMANS P. et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol. Motil., 2009, 21: 378-88.
MOAYYEDI P., DELANEY B.C., VAKIL N., FORMAN D., TALLEY N.J. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology, 2004, 127: 1329-37.
MÖNNIKES H., SCHWAN T., VAN RENSBURG C., STRASZAK A., THEEK C., SANDER P. et al. Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastrooesophageal reflux disease. Aliment. Pharmacol. Ther., 2012, 35: 1279-89.
KRIENGKIRAKUL C., PATCHARATRAKUL T., GONLACHANVIT S. The Therapeutic and Diagnostic Value of 2-week High Dose Proton Pump Inhibitor Treatment in Overlapping Non-erosive Gastroesophageal Reflux Disease and Functional Dyspepsia Patients. J. Neurogastroenterol. Motil., 2012, 18: 174-80.
XIAO Y-L., PENG S., TAO J., WANG A.-J., LIN J.-K., HU P.-J. et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am. J. Gastroenterol., 2010, 105: 2626-31.
DONNELLAN C., SHARMA N., PRESTON C., MOAYYEDI P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst. Rev., 2005: CD003245.
PACE F., TONINI M., PALLOTTA S., MOLTENI P., PORRO G.B. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken "on-demand". Aliment. Pharmacol. Ther., 2007, 26: 195-204.
GERSON L.B., ROBBINS A.S., GARBER A., HORNBERGER J., TRIADAFILOPOULOS G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am. J. Gastroenterol., 2000, 95: 395-407.
DORE M.P., MARAGKOUDAKIS E., FRALEY K., PEDRONI A., TADEU V., REALDI G. et al. Diet, lifestyle and gender in gastro-esophageal reflux disease. Dig. Dis. Sci., 2008, 53: 2027-32.
NOWAK M., BÜTTNER P., RAASCH B., DANIELL K., MC CUTCHAN C., HARRISON S. Lifestyle changes as a treatment of gastroesophageal reflux disease: a survey of general practitioners in North Queensland, Australia. [Internet]. Ther. Clin. Risk Manag., 2005 [cited 2012 Oct 5], 1: 219-24.
KHAN B.A., SODHI J.S., ZARGAR S.A., JAVID G., YATTOO G.N., SHAH A. et al. Effect of bed head elevation during sleep in symptomatic patients of nocturnal gastroesophageal reflux. J. Gastroenterol. Hepatol., 2012, 27: 1078-82.
JOHNSON T., GERSON L., HERSHCOVICI T., STAVE C., FASS R. Systematic review: the effects of carbonated beverages on gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther., 2010, 31: 607-14.
FESTI D., SCAIOLI E., BALDI F., VESTITO A., PASQUI F., DI BIASE A.R. et al. Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J. Gastroenterol., 2009, 15: 1690-701.
NOWAK M., BÜTTNER P., HARRISON S., DANIELL K., RAASCH B., SPEARE R. Effectiveness of lifestyle measures in the treatment of gastroesophageal reflux disease-a case series. [Internet]. Ther. Clin. Risk Manag., 2006, 2: 329-34.
CARO J.J., SALAS M., WARD A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. [Internet]. Clin. Ther., 2001 [cited 2012 Jul 27], 23: 998-1017.
KIRCHHEINER J., GLATT S., FUHR U., KLOTZ U., MEINEKE I., SEUFFERLEIN T. et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur. J. Clin. Pharmacol., 2009, 65: 19-31.
KAHRILAS P.J., HOWDEN C.W., HUGHES N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am. J. Gastroenterol., 2011, 106: 1419-25.
FRESTON J.W. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor. Am. J. Med., 2004, 117 Suppl.: 14S-22S.
BLUME H., DONATH F., WARNKE A., SCHUG B.S. Pharmacokinetic drug interaction profiles of proton pump inhibitors. [Internet]. Drug Saf., 2006 [cited 2012 Sep 30], 29: 769-84.
THOMSON A.B.R., SAUVE M.D., KASSAM N., KAMITAKAHARA H. Safety of the long-term use of proton pump inhibitors. World J. Gastroenterol., 2010, 16: 2323-30.
ABRAHAM N.S. Prescribing proton pump inhibitor and clopidogrel together: current state of recommendations. Curr. Opin. Gastroenterol., 2011, 27: 558-64.
DOUGLAS I.J., EVANS S.J.W., HINGORANI A.D., GROSSO A.M., TIMMIS A., HEMINGWAY H. et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ, 2012, 345: e4388.
KWOK C.S., JEEVANANTHAM V., DAWN B., LOKE Y.K. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: Meta-analysis. Int. J. Cardiol., 2012 DOI: 10.1016/j.ijcard.2012.03.085
JASPERS FOCKS J., BROUWER M.A., VAN OIJEN M.G.H., LANAS A., BHATT D.L., VERHEUGT F.W.A. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome-a systematic review. Heart, 2012 DOI: 10.1136/heartjnl-2012-302371
DREPPER M.D., SPAHR L., FROSSARD J.L. Clopidogrel and proton pump inhibitors - where do we stand in 2012? World J. Gastroenterol., 2012, 18: 2161-71.
FASS R., MURTHY U., HAYDEN C.W., MALAGON I.B., PULLIAM G., WENDEL C. et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastrooesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-ce [Internet]. Aliment. Pharmacol. Ther., 2000, 14: 1595-603.
HERSHCOVICI T., FASS R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr. Opin. Gastroenterol., 2010, 26: 367-78.
CHARBEL S., KHANDWALA F., VAEZI M.F. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am. J. Gastroenterol., 2005, 100: 283-9.
KARAMANOLIS G., VANUYTSEL T., SIFRIM D., BISSCHOPS R., ARTS J., CAENEPEEL P. et al. Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig. Dis. Sci., 2008, 53: 2387-93.
FURUTA T., SHIMATANI T., SUGIMOTO M., ISHIHARA S., FUJIWARA Y., KUSANO M. et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research G. J. Gastroenterol., 2011, 46: 1273-83.
JONES R., PATRIKIOS T. The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor. Int. J. Clin. Pract., 2008, 62: 1844-50.
KINOSHITA Y., HONGO M. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am. J. Gastroenterol., 2012, 107: 522-30.
HEMMINK G.J.M., BREDENOORD A.J., WEUSTEN B.L. A M., MONKELBAAN J.F., TIMMER R., SMOUT A.J.P.M. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: "on" or "off" proton pump inhibitor? Am. J. Gastroenterol., 2008, 103: 2446-53.
MAINIE I., TUTUIAN R., CASTELL D.O. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J. Clin. Gastroenterol., 2008, 42: 676-9.
HEIDELBAUGH J.J., METZ D.C., YANG Y.-X. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int. J. Clin. Pract., 2012, 66: 582-91.
GAWRON AJ., ROTHE J., FOUGHT AJ., FAREEDUDDIN A., TOTO E., BORIS L. et al. Many Patients Continue Using Proton Pump Inhibitors After Negative Results From Tests for Reflux Disease. Clin. Gastroenterol. Hepatol., 2012 DOI: 10.1016/j.cgh.2012.02.012
QVIGSTAD G., WALDUM H. Rebound hypersecretion after inhibition of gastric acid secretion. Basic Clin. Pharmacol. Toxicol., 2004, 94: 202-8.
FOSSMARK R., JOHNSEN G., JOHANESSEN E., WALDUM HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment. Pharmacol. Ther., 2005, 21: 149-54.
NIKLASSON A., LINDSTRÖM L., SIMRÉN M., LINDBERG G., BJÖRNSSON E. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am. J. Gastroenterol., 2010, 105: 1531-7.
REIMER C., SØNDERGAARD B., HILSTED L., BYTZER P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology, 2009, 137: 80-7.
NIV Y. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients. Med. Hypotheses, 2011, 77: 451-2.
INADOMI J.M., MCINTYRE L., BERNARD L., FENDRICK A.M. Step-down from multiple-to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am. J. Gastroenterol., 2003, 98: 1940-4.
TYTGAT G.N., MCCOLL K., TACK J., HOLTMANN G., HUNT R.H., MALFERTHEINER P. et al. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther., 2008, 27: 249-56.
ALI T., ROBERTS D.N., TIERNEY W.M. Long-term safety concerns with proton pump inhibitors. Am. J. Med., 2009, 122: 896-903.
VAKIL N. Acid inhibition and infections outside the gastrointestinal tract. Am. J. Gastroenterol., 2009, 104 Suppl: S17-20.
BAVISHI C., DUPONT H.L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment. Pharmacol. Ther., 2011, 34: 1269-81.
DUPONT H.L., ERICSSON C.D., FARTHING M.J.G., GORBACH S., PICKERING L.K., ROMBO L. et al. Expert review of the evidence base for prevention of travelers' diarrhea. J. Travel. Med., 2009, 16: 149-60.
JANARTHANAN S., DITAH I., ADLER D.G., EHRINPREIS M.N. Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis. Am. J. Gastroenterol., 2012, 107: 1001-10.
HOWELL M.D., NOVACK V., GRGURICH P., SOULLIARD D., NOVACK L., PENCINA M. et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med., 2010, 170: 784-90.
SULTAN N., NAZARENO J., GREGOR J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. [Internet]. Can. J. Gastroenterol., 2008, 22: 761-6.
GIULIANO C., WILHELM S.M., KALE-PRADHAN P.B. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert. Rev. Clin. Pharmacol., 2012, 5: 337-44.
MEIJVIS S.C. A., CORNIPS M.C. A., VOORN G.P., SOUVEREIN P.C., ENDEMAN H., BIESMA D.H. et al. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. Eur. Respir. J., 2011, 38: 1165-72.
TARGOWNIK L.E., LESLIE W.D., DAVISON K.S., GOLTZMAN D., JAMAL S.A., KREIGER N. et al. The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos). Am. J. Gastroenterol., 2012: 1-9.
YU E.W., BAUER S.R., BAIN P.A., BAUER D.C. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am. J. Med., 2011, 124: 519-26.
KWOK C.S., YEONG J.K.-Y., LOKE Y.K. Meta-analysis: risk of fractures with acid-suppressing medication. Bone, 2011, 48: 768-76.
KHALILI H., HUANG E.S., JACOBSON B.C., CAMARGO C.A., FESKANICH D., CHAN A.T. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ, 2012, 344: e372-e372.
NGAMRUENGPHONG S., LEONTIADIS G.I., RADHI S., DENTINO A., NUGENT K. Proton pump inhibitors and risk of fracture: a systematic retack view and meta-analysis of observational studies. Am. J. Gastroenterol., 2011, 106: 1209-18; quiz 1219.
YANG Y.-X., METZ D.C. Safety of proton pump inhibitor exposure. Gastroenterology, 2010, 139: 1115-27.